3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chi

3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030

Animal cell cultures represent an integral part of the drug discovery and development process. The conventional 2 dimensional (2D) cell culturing format is still extensively used in early stage research and is instrumental in establishing initial proof-of-concept and validating mechanisms of action of pharmacological leads. However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research. This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases. Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

The “3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030” report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
 An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
 A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence.
 A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence.
 A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence.
 An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.
 Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook.
 An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.
 An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
 An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.
 An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.
 An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
 Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:
 Brigitte Angres (Co-founder, Cellendes)
 Bill Anderson (President and CEO, Synthecon)
 Anonymous (President and CEO, Anonymous)
 Anonymous (Co-founder and Vice President, Anonymous)
 Scott Brush (Vice President, BRTI Life Sciences)
 Malcolm Wilkinson (Managing Director, Kirkstall)
 Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
 Tanya Yankelevich (Director, Xylyx Bio)
 Jens Kelm (Chief Scientific Officer, InSphero)
 Walter Tinganelli (Group Leader, GSI)
 Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
 Who are the leading industry players engaged in the development of 3D cell culture products?
 What are the most popular 3D cell culture products?
 What are the different applications for which 3D cell culture products are currently being developed?
 What are the key factors that are likely to influence the evolution of this market?
 What is the trend of capital investments in the 3D cell culture systems market?
 Which partnership models are commonly adopted by stakeholders in this industry?
 How is the COVID-19 pandemic likely to impact the 3D cell culture systems market?
 How is the current and future opportunity likely to be distributed across key market segments?
 What are the anticipated future trends related to 3D cell culture systems market?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term.
Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis.

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions)
Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies / organizations have been mentioned in this report.

1. 101Bio
2. 3D Biomatrix
3. 3D Biotek
4. 3D Biotechnology Solutions
5. 3Dnamics
6. 4Dcell
7. 4titude
8. AbbVie Ventures
9. abc biopply
10. ABL Europe
11. Åbo Akademi University
12. Abstraction Ventures
13. Abzena
14. Accellta
15. Advanced BioMatrix
16. Advanced Regenerative Manufacturing Institute (ARMI)
17. Advanced Scientifics
18. Aetos Biologics
19. Afirmus Biosource
20. AGC
21. Agency for Science, Technology and Research (A*STAR)
22. AIM Biotech
23. Akero Therapeutics
24. Akron Biotech
25. Alector
26. Allevi
27. Alnylam Pharmaceuticals
28. American Laboratory Products
29. Alphabioregen
30. ALS Investment Fund
31. AlveoliX
32. AMS Biotechnology
33. AnaPath Services
34. Angel Investors
35. AngelMD
36. Angels 5K
37. Angels in MedCity
38. Angels Santé
39. Anthrogenesis
40. Aquitaine Science Transfert
41. Aquiti Gestion
42. AR Brown
43. ARL Design
44. ARTeSYN Biosolutions
45. AstraZeneca
46. Arizona State University
47. ATEL Ventures
48. Atera
49. Avantor
50. AxoSim
51. AXT
52. Axxicon
53. BASF
54. Bayer
55. B-CULTURE
56. BEOnChip
57. Bio-Byblos Biomedical
58. BioCat
59. BioConcept
60. BIOFABICS
61. Biogelx
62. Bioinspired Solutions
63. BioInvent International
64. BIOKÉ
65. BioLamina
66. Biomaterials USA
67. Biomerix
68. BiomimX
69. Biopredic International
70. BioTek Instruments
71. BiSS TGT
72. Bonus BioGroup
73. Bpifrance
74. BRAIN
75. BrainXell
76. Brammer Bio
77. Braveheart Investment Group
78. Bristol-Myers Squibb
79. Broad Institute
80. BRTI Life Sciences
81. Cambridge Bioscience
82. University of Cambridge
83. CarThera
84. Cedars-Sinai Medical Center
85. Celartia
86. Cell Applications
87. Cell Culture
88. CELLEC BIOTEK
89. Cellendes
90. Cellevate
91. CELLnTEC
92. CellSpring
93. CellSystems
94. CelVivo
95. Center for the Advancement of Science in Space
96. CESCO Bioengineering
97. Charles River Laboratories
98. Cherry Biotech
99. China Regenerative Medicine International
100. CITIC Securities
101. CN Bio Innovations
102. CN Innovations
103. Collagen Solutions
104. Comune di Milano
105. Corning Life Sciences
106. Cosmo Bio
107. CELLphenomics
108. Commonwealth Serum Laboratories
109. Curi Bio
110. Cyprio
111. Cyprotex
112. Cytiva
113. Danaher
114. Deepbridge Capital
115. Demcon
116. United States Department of Defense
117. Development Bank of Wales
118. DiPole Materials
119. Downing Ventures
120. Government of the Netherlands
121. Executive Agency for Small and Medium-sized Enterprises (EASME)
122. EBERS
123. Ectica Technologies
124. EDITHGEN
125. Electrospinning
126. Emulate
127. Enso Discoveries
128. Eppendorf
129. Esco Aster
130. Esperante
131. Ethicon
132. European Life Sciences Growth Fund (ELSGF)
133. European Commission
134. European Union
135. Eurostars
136. EU-ToxRisk
137. Eva Scientific
138. Evotec
139. faCellitate
140. Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
141. Fennik Life Sciences
142. Ferentis
143. FHNW University
144. FiberCell Systems
145. Fibralign
146. Finep
147. Finesse Solutions
148. Finovam Gestion
149. Flexcell International
150. Foundation for Technological Innovation
151. Founder
152. Founders Fund
153. Freeline
154. French Government
155. Frequency Therapeutics
156. FroggaBio
157. Fujifilm
158. FUJIFILM Wako Pure Chemical
159. Funakoshi
160. Gabriel Investments
161. Galapagos
162. GALIA Gestion
163. Gamma 3
164. Gelmetix
165. Gelomics
166. Gemini Bio
167. Gemstone Biotherapeutics
168. Genome Institute of Singapore
169. Georgia Research Alliance
170. Global Cell Solutions
171. Government of China
172. Great Stuff Ventures
173. GSI
174. GlaxoSmithKline
175. HµREL
176. Hamilton
177. Harvard Apparatus
178. Harvard College
179. HCS Pharma
180. Helvoet
181. Heraeus Medical
182. Hesperos
183. Histogenics
184. Human Models for Analysis of Pathways (HMAPs) Center
185. Hokkaido Soda
186. HP Wild Holding
187. Hubrecht Organoid Technology
188. Humanetics
189. Hyamedix
190. ibidi
191. IMSS-Gulf Bio Analytical
192. INITIO CELL
193. Innovate UK
194. Innovation Fund Denmark
195. Inova Health System
196. inRegen
197. InSphero
198. Invitrocue
199. InvivoSciences
200. Ionis Pharmaceuticals
201. Irdi Soridec Gestion
202. Janssen Biotech
203. Japan Vilene Company
204. Jellagen Marine Biotechnologies
205. Johns Hopkins University
206. JRI Orthopaedics
207. Kero
208. Kim & Friends
209. Kirkstall
210. KIYATEC
211. KOKEN
212. Koninklijke Nederlandse Akademie Van Wetenschappen
213. Kuraray
214. LabCorp
215. Laconia
216. LAMBDA Laboratory Instruments
217. Lantern Pharma
218. Lawrence J. Ellison Institute for Transformative Medicine
219. LBA Healthcare Management
220. Lena Biosciences
221. LFB Biomanufacturing
222. Life Technologies
223. Lifecore Biomedical
224. LifeNet Health
225. Laboratory for Integrated Micro Mechatronic Systems
226. Lineage Cell Therapeutics
227. Locate Bio
228. London School of Hygiene & Tropical Medicine
229. Lonza
230. Lund University
231. LuoLabs
232. Manchester BIOGEL
233. University of Mannheim
234. Maryland Momentum Fund
235. Massachusetts Institute of Technology
236. MassChallenge
237. MatTek Life Sciences
238. MBL International
239. GlassWall Syndicate
240. Menicon Life Science
241. Merck Accelerator
242. Merck Millipore
243. Michael J. Fox Foundation
244. Michigan Technological University
245. Micronit
246. MicroTissues
247. Midven
248. MIMETAS
249. Minerva Business Angel Network
250. Molecular Devices
251. Maryland Stem Cell Research Fund (MSCRF)
252. MTTlab
253. Nanobiose
254. Nano Dimension
255. Nanofiber Solutions
256. Nanogaia
257. National Aeronautics and Space Administration
258. National Center for Advancing Translational Sciences
259. National Institute of Health
260. National Institute on Aging
261. National Institutes for Food and Drug Control
262. National Science Foundation
263. National University Hospital
264. National University of Singapore
265. National Centre for the Replacement, Refinement and Reduction of Animals in Research
266. Neuromics
267. New Orleans BioFund
268. Newable Private Investing
269. Nexcelom Bioscience
270. Nord France Amorquage
271. Invest Northern Ireland
272. Northwick Park Institute for Medical Research
273. Nortis
274. Nova Biomedical
275. Novartis Venture Fund
276. Noviocell
277. Nucleus Biologics
278. NYU Winthrop Hospital
279. Olaregen Therapeutix
280. OMNI Life Science
281. Oregon Health & Science University
282. Organovo
283. Orthomimetics
284. OS Fund
285. Oxford MEStar
286. Pairnomix
287. Pall Corporation
288. Path BioAnalytics
289. PBS Biotech
290. Peak Capital Advisors
291. Pelo Biotech
292. Pensees
293. PepGel
294. Percell Biolytica
295. PerkinElmer
296. Pfizer
297. PHI
298. Pitch@Palace
299. PL BioScience
300. Plasticell
301. Pluristem Therapeutics
302. Portugal Ventures
303. Precision Biologics
304. Premedical Laboratories
305. Primorigen Biosciences
306. Principia SGR
307. ProBio
308. ProBioGen
309. Prodizen
310. PromoCell
311. Protista International
312. QGel Bio
313. QIAGEN (Suzhou)
314. Quintech Life Sciences
315. PT Rajawali Medika Mandiri
316. RASA
317. React4life
318. Real Research
319. RealBio Technology
320. Regemat3D
321. Repligen
322. REPROCELL
323. Research Without Animal Experiment
324. Revivocell
325. Rigenerand
326. Roche
327. RoosterBio
328. Roswell Park Comprehensive Cancer Center
329. Sanofi Ventures
330. SARSTEDT
331. Sartorius
332. S-BIO
333. ScienCell
334. SciFi VC
335. SciKon Innovation
336. Scinus Cell Expansion
337. Scottish Investment Bank
338. Seres Therapeutics
339. Shanghai Cienle Medical Technology
340. Shanghai Institute of Materia Medica
341. Shanghai Institute of Biochemistry and Cell Biology
342. Siemens Technology
343. Sigma-Aldrich
344. SKE Research Equipment
345. SmiLe Incubator
346. SoloHill Engineering
347. Spheritech
348. Spiber Technologies
349. Start-Up Chile
350. State Key Laboratory of Experimental Hematology
351. StemCell Systems
352. STEMCELL Technologies
353. Stemmatters
354. StemoniX
355. StemTek Therapeutics
356. SUN bioscience
357. Commission for Technology and Innovation
358. Swiss Federal Laboratories for Materials Science and Technology
359. SyndicateRoom
360. Synthecon
361. SynVivo
362. TA Instruments
363. Takeda
364. Tantti Laboratory
365. tebu-bio
366. TEDCO
367. Terumo
368. Texas Tech University Health Sciences Center
369. Development Bank of Wales
370. Ministry of Higher Education, Research and Innovation (France)
371. The Idea Village
372. Institute for Molecular Medicine Finland
373. Mario Negri Institute for Pharmacological Research
374. University of Alberta
375. University of Bath
376. University of Brescia
377. University of Bristol
378. University of Manchester
379. University of Milan
380. University of Strathclyde
381. University of Zurich
382. TheWell Bioscience
383. Thermo Fisher Scientific
384. Tianjin Weikai Biological Engineering
385. Tissue Click
386. TissueLabs
387. TissUse
388. Tokyo Future Style
389. TPG
390. TreeFrog Therapeutics
391. Trevigen
392. Triumvirate Environmental
393. Technical University of Berlin
394. Twinhelix
395. UK Innovation & Science Seed Fund
396. Science and Technology Facilities Council (STFC)
397. UK Science and Technology Facilities Council
398. University of Genoa
399. University College London
400. University Hospital Zurich
401. Stanford University
402. University of Arkansas for Medical Sciences
403. University of California
404. University of Central Florida
405. University of Nottingham
406. The University of Sheffield
407. University of Washington School of Pharmacy
408. University of Zurich
409. UPM Biomedicals
410. U.S. Small Business Administration
411. UW Medicine
412. VA Portland Health Care System
413. Vanderbilt University
414. Venture Kick
415. VentureSouth
416. Venturecraft
417. Viscofan BioEngineering
418. Visikol
419. Vivo Biosciences
420. VWR
421. Wake Forest Institute for Regenerative Medicine
422. Women Who Tech
423. XAnge
424. Xenos
425. XP Biomed
426. Xylyx Bio
427. Zhejiang University
428. zPREDICTA